Gold prices slip lower; consolidating after recent gains
Laurent Moll, the Chief Operating Officer of Arteris , Inc. (NASDAQ:AIP), recently sold 654 shares of the company’s common stock. The transaction, which took place on March 3, 2025, was valued at approximately $5,482, with shares sold at an average price of $8.3833 each. According to InvestingPro data, this sale comes as the stock has declined over 10% in the past week, though it maintains impressive gross profit margins of nearly 90%.
The sale was conducted to satisfy Moll’s tax liability resulting from the release of restricted stock units. Following this transaction, Moll retains ownership of 487,729 shares in the company. InvestingPro analysis suggests the stock is currently overvalued, with analyst price targets ranging from $11 to $16 per share. For deeper insights into Arteris’s valuation and 7 additional key ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Arteris, Inc has garnered attention from analysts with updates on its stock price targets and product developments. Jefferies analyst Blayne Curtis raised the price target for Arteris to $11.00 from $7.00, maintaining a Hold rating due to recent progress in the microcontroller unit (MCU) market, including a significant win at IFX. This progress is expected to contribute positively to Arteris’ financial performance, with the introduction of the FlexGen solution potentially providing a 30% average selling price uplift per license. However, Jefferies remains cautious, citing lower-than-expected 2025 guidance and the need for more evidence of improved execution in MCU and FlexGen license sales.
Meanwhile, Northland analysts increased their price target for Arteris to $16.00 from $14.00, maintaining an Outperform rating. They noted that Arteris reported revenue that met expectations for the quarter and provided guidance in line with forecasts. The company’s bookings reached approximately $33.6 million for the quarter, with a book-to-bill ratio of 2.2:1, and the FlexNoC 5 product accounted for a significant portion of interconnect licenses. The recent launch of the FlexGen product was a key factor in Northland’s revised price target, as it offers a 30% ASP uplift and is being evaluated by 13 customers. Analysts at Northland expressed confidence in Arteris’ market position and the potential positive impact of FlexGen on the company’s financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.